Literature DB >> 22484633

Consensus on treatment of endometrium carcinoma with brachytherapy.

J L Guinot1, J Pérez-Calatayud, J M Azcoaga, I Herruzo, C Bodineau, A Rovirosa, V Crispín, P Galán, E González-Patiño, J Pérez-Regadera, A Polo.   

Abstract

Radiotherapy (RT) is commonly used as adjuvant treatment following hysterectomy and double oophorectomy in endometrial carcinoma. Prophylactic vaginal brachytherapy (BT) is the most common treatment in BT units. The PORTEC and GOG 99 studies have attempted to clarify the indications of BT and postoperative external RT, changing treatment standards. However, prophylactic BT regimens are very varied and there is currently no consensus on how to treat patients in terms of dose per fraction and number of fractions. Moreover, unoperated cases of endometrium are uncommon and there is limited experience in their treatment with BT. The 9th Consensus Meeting of the SEOR and SEFM Brachytherapy Group, held in Malaga on 11 March 2011, was therefore dedicated to "Brachytherapy in Endometrial Carcinoma". This article presents the consensus on treatment of endometrial carcinoma in operated (prophylactic vaginal BT) and unoperated (endouterine BT) patients.

Entities:  

Mesh：

Year:  2012        PMID： 22484633     DOI： 10.1007/s12094-012-0794-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  18 in total

1.  Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy.

Authors:  J Fanning
Journal:  Gynecol Oncol       Date:  2001-08       Impact factor: 5.482

2.  Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial.

Authors:  G H Eltabbakh; M S Piver; R E Hempling; K H Shin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-05-01       Impact factor: 7.038

3.  The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium.

Authors:  S Nag; B Erickson; S Parikh; N Gupta; M Varia; G Glasgow
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-10-01       Impact factor: 7.038

4.  Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study.

Authors:  W T Creasman; C P Morrow; B N Bundy; H D Homesley; J E Graham; P B Heller
Journal:  Cancer       Date:  1987-10-15       Impact factor: 6.860

5.  Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.

Authors:  R A Nout; V T H B M Smit; H Putter; I M Jürgenliemk-Schulz; J J Jobsen; L C H W Lutgens; E M van der Steen-Banasik; J W M Mens; A Slot; M C Stenfert Kroese; B N F M van Bunningen; A C Ansink; W L J van Putten; C L Creutzberg
Journal:  Lancet       Date:  2010-03-06       Impact factor: 79.321

6.  Postoperative vaginal vault brachytherapy for node-negative Stage II (occult) endometrial carcinoma.

Authors:  T Y Ng; J L Nicklin; L C Perrin; R Cheuk; A J Crandon
Journal:  Gynecol Oncol       Date:  2001-05       Impact factor: 5.482

7.  Three or four fractions of 4-5 Gy per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma.

Authors:  Angeles Rovirosa; Carlos Ascaso; Alberto Sánchez-Reyes; Antonio Herreros; Rosa Abellana; Jaume Pahisa; Jose Antonio Lejarcegui; Albert Biete
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-26       Impact factor: 7.038

Review 8.  Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis.

Authors:  N Johnson; P Cornes
Journal:  BJOG       Date:  2007-09-05       Impact factor: 6.531

Review 9.  Adjuvant radiotherapy for stage I endometrial cancer.

Authors:  A Kong; N Johnson; P Cornes; I Simera; M Collingwood; C Williams; H Kitchener
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

Review 10.  Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis.

Authors:  P Blake; Ann Marie Swart; J Orton; H Kitchener; T Whelan; H Lukka; E Eisenhauer; M Bacon; D Tu; M K B Parmar; C Amos; C Murray; W Qian
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321
View more
  8 in total

1.  Endometrial adenocarcinoma in one horn of a didelphic uterus with vaginal duplication.

Authors:  Daniel Vázquez Vicente; Hugo Ariel Di Fiore; Jesús Garcia-Foncillas; Javier Plaza Arranz
Journal:  BMJ Case Rep       Date:  2014-05-19

2.  Three or four fractions per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma. The long-term results on vaginal relapses and toxicity.

Authors:  I Valduvieco; Á Rovirosa; A Herreros; I Romera; I Ríos; C Ascaso; A Sánchez-Reyes; M Arenas; J Pahisa; A Biete
Journal:  Clin Transl Oncol       Date:  2012-12-21       Impact factor: 3.405

3.  Vaginal-cuff control and toxicity results of a daily HDR brachytherapy schedule in endometrial cancer patients.

Authors:  I Ríos; A Rovirosa; C Ascaso; I Valduvieco; A Herreros; L Castilla; S Sabater; K Holub; J Pahisa; A Biete; M Arenas
Journal:  Clin Transl Oncol       Date:  2015-12-11       Impact factor: 3.405

4.  Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma.

Authors:  Angeles Rovirosa; Izaskun Valduvieco; Carlos Ascaso; Antonio Herreros; Carlos Bautista; Ingrid Romera; Meritxell Arenas; Jaume Pahisa; Albert Biete
Journal:  Clin Transl Oncol       Date:  2012-07-19       Impact factor: 3.405

5.  Preliminary results of a vaginal constraint for reducing G2 late vaginal complications after postoperative brachytherapy in endometrial cancer: a prospective analysis.

Authors:  Y Zhang; G Gomez; C Ascaso; A Herreros; B Fornes; J Mases; J Rochera; L Tagliaferri; S Sabater; A Torne; A Biete; Á Rovirosa
Journal:  Clin Transl Oncol       Date:  2021-12-01       Impact factor: 3.340

6.  Postoperative endometrial carcinoma treated with external beam irradiation plus vaginal-cuff brachytherapy. Is there a dose relationship with G2 vaginal complications?

Authors:  Yaowen Zhang; Carlos Ascaso; Antonio Herreros; Joan Sánchez; Sebastia Sabater; Marta Del Pino; Yan Li; Gabriela Gómez; Aureli Torné; Albert Biete; Ángeles Rovirosa
Journal:  Rep Pract Oncol Radiother       Date:  2020-01-14

7.  Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2.

Authors:  Hsien-Ming Wu; Hsin-Shih Wang; Hong-Yuan Huang; Chyong-Huey Lai; Chyi-Long Lee; Yung-Kuei Soong; Peter Ck Leung
Journal:  BMC Cancer       Date:  2013-06-20       Impact factor: 4.430

8.  Late G2 vagina toxicity in post-operative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2 Gy per fraction(α/β=3Gy) at 2 cm3 of vagina.

Authors:  María Del Valle Aguilera; Ángeles Rovirosa; Carlos Ascaso; Antonio Herreros; Joan Sánchez; Julia Garcia-Migue; Stephanía Cortes; Eduardo Agusti; Cristina Camacho; Yaowen Zhang; Yan Li; Sebastià Sabater; Aureli Torne; Meritxell Arenas
Journal:  J Contemp Brachytherapy       Date:  2018-02-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.